Abnormal LFTs in migrant populations. Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital

Similar documents
2. Liver blood tests and what they mean p2 Acute and chronic liver screen

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Managing abnormal LFTs in Primary care

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

LFTs: an update A MacGilchrist PLIG meeting 31st January 2019

Patterns of abnormal LFTs and their differential diagnosis

Investigating and Referring Incidental Findings of Abnormal Liver Tests

Patterns of abnormal LFTs and their differential diagnosis

EAST LONDON INTEGRATED CARE

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Liver Network. Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities

Abnormal LFTs and NAFLD. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London

Liver Network Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities

Liver disease in 2017: challenges and opportunities

EVALUATION OF ABNORMAL LIVER TESTS

Management of Hepatitis C

Management of Hepatitis C

Module 1 Introduction of hepatitis

Outline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018

Physical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford

Chronic Hepatitis. Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh

Management of Hepatitis B - Information for primary care providers

Management of Patients with Chronic Hepatitis B: The Alaska Experience

Hepatology for the Nonhepatologist

Clinical dilemmas in HBeAg-negative CHB

CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE

Update on Hepatitis B and Hepatitis C

Hepatitis B screening and surveillance in primary care

Management of Hepatitis C

Management of Hepatitis B

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

Treatment of HCC in real life-chinese perspective

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Identification of patients with chronic hepatitis B/C the UK

Patient Information Leaflet Non-Alcoholic Fatty Liver Disease (NAFLD) fatty-liver

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

Treatment for Hepatitis B

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

Investigating general liver disease/transaminitis

Objectives. Five Take Home Pearls. We Can Cure Hepatitis C. Hepatitis C Screening, Treatment and the Family Physician 10/15/2018

Hepatitis B infection

Mr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK

Hepatitis C Update on New Treatments

A Rational Evidence-based Approach to Abnormal Liver Tests

Viral Hepatitis. Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology

in pregnancy Document Review History Version Review Date Reviewed By Approved By

HBV in HIV Forgotten but not Gone

Biochemical Investigations in Liver Disease. Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Liver Disease. Is it a big problem? Who is affected What causes it What is required. Community Hepatology Practical tips. Change of Tempo & Style

March 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D

Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1

What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon

PILOT. (Med 01) Patient Details (attach Addressograph): , # # $% # -! .//01 2 $ %& '( % $ ) * ##!! %#!! *!! Genotype: HbcAb (core antibody) HAV status

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Viral hepatitis and Hepatocellular Carcinoma

Mrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014

Approach to Abnormal Liver Tests

Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화

2013 UPDATES IN HEPATITIS B & C

Chronic Hepatitis C The Patient s Perspective

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Transmission of HCV in the United States (CDC estimate)

S401- Updates in the Treatments of Hepatitis B & C

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

Learning Objectives. After attending this presentation, participants will be able to:

NICE guideline Published: 6 July 2016 nice.org.uk/guidance/ng49

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

9/28/2016. Elevated Liver Function Tests: A Case Based Approach. Objectives. Identify patterns of abnormal liver function tests

CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

CASES FOR DISCUSSION. Yohannes B

Liver Function Testing. in primary care. Quiz Feedback

Toronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action

Routine blood- borne virus testing for HIV, hepatitis B & C in the emergency department: the new normal?

Tumor incidence varies significantly, depending on geographical location.

At Least 1 in 5 Patients in Your Practice Have Fatty Liver

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Anaemia Pathway. Anaemia. Type of Anaemia Check Haematinics (Iron stores,b12,folate) Fit for endoscopies. endoscopies yes no. Non Iron Deficient

Liver Disease. Annual Report. Cardiff and Vale Health Board. April 2016

Pretreatment Evaluation

Liver 102: Injury and Healing

Hepatology For The Nonhepatologist

Review: How to work up your patient with Hepatitis C

Hepatocellular Carcinoma. Markus Heim Basel

Programs for Chronic HBV and HCV in Alaska Natives

World Health Organization. Western Pacific Region

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Pretreatment Evaluation

World Health Organization. Western Pacific Region

Hepatitis C. Request a Test. Benefits of testing in AOD services to improve treatment uptake

Alcoholism and Alcohol Liver Disease from a Transplant Hepatology Perspective

Abnormal LFTs GP CME 2014 Workshop Fri 55 mins. Dr Alasdair Patrick Macmurray Center GP CME 2014

Transcription:

Abnormal LFTs in migrant populations Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital

www.migrationobservatory.ox.ac.uk Migrants in London

Migrants in London

Migrants in London

Common liver diseases in migrant populations Viral Hepatitis Alcoholic liver disease Non-alcoholic steatohepatitis (NASH) Diagnostic and treatment challenges specific to migrant populations

Scottish Macedonian English Indian Bulgarian Burmese

Summary of Pathway Isolated hyperbilirubinaemia Gilbert s. Exclude haemolysis Jaundice with other abnormal LFTs (Bilirubin>40) urgent referral ALT>300 urgent discussion and referral Cholestatic LFTs (raised GGT, ALP) or hepatitic picture (ALT<300) request USS and liver panel then refer if abnormalities detected: HBsAg HCV Ab Autoantibodies Ferritin/ TF saturation Caeruloplasmin Immunoglobulins α1-antitrypsin If normal screen for alcohol excess give lifestyle advice and monitor LFTs If fatty liver on USS is the only abnormality see NAFLD pathway

Liver disease with normal LFTs Alazawi W et al. Br J Gen Pract 2014;64:e694-e702

Prevalence of NAFLD, ALD, HBV and HCV in different ethnic groups within the general population. Alazawi W et al. Br J Gen Pract 2014;64:e694-e702

NAFLD Pathway

Summary of NAFLD Pathway Use the FIB4 test to identify patients at high risk of advanced fibrosis ( Age x AST ) / ( Platelets x ALT ) Non-invasive tests (e.g. ELF) for patients with intermediate FIB4 score High FIB4/positive non-invasive test should be referred to hepatology Low FIB4/negative non-invasive fibrosis test managed in primary care: Treat metabolic syndrome components (hypercholesterolaemia, diabetes, hypertension) Lifestyle modification diet, exercise, alcohol Aim 10% weight loss Annual LFTs and reassess fibrosis risk if LFTs remain abnormal

Weight loss a level playing field? 3 components: Reduced calorie diet Increased physical activity Maintenance strategy (e.g. group monitoring) Tailored delivery by trained interventionalist (physical trainer, dietician, psychologist) produces better weight loss than advice alone BUT Short-term weight loss (6 months) almost always followed by slow regain of initial weight over 1-2 years No evidence for weight loss programmes tailored to ethnic or cultural minorities

Weight loss a level playing field? Gill JM, Celis-Morales CA, Ghouri N. Physical activity, ethnicity and cardio-metabolic health: does one size fit all? Atherosclerosis. 2014 Feb;232(2):319-33.

Alcohol Alazawi W et al. Br J Gen Pract 2014;64:e694-e702

WHO status report on alcohol and health in 35 European countries 2013 ALD in the EU

Alcohol in Migrant Populations Pattern Low rates of drinking but high consumption in drinkers High rates of drinking and high consumption Low rates of drinking and low consumption in drinkers Rising rates and consumption Ethnic Group Pakistani men, mixed ethnicity men White ethnicities (Irish, Scottish, Polish, English), Sikh Men, Chinese, Bangladeshi, Hindu Indian women and Irish women of high socioeconomic status Ethnicity and alcohol: A review of the UK literature. Middlesex University 2010

Alcohol in Migrant Populations Rates and pattern of consumption in country of birth is a poor indicator of alcohol consumption in the UK Migrants adopt local consumption patterns 2 nd generation not distinguishable from general population Alcohol use associated with migration itself- social isolation, anxiety and depression Ethnicity and alcohol: A review of the UK literature. Middlesex University 2010

Alcohol screening and treating A QOF for alcohol consumption screening and brief intervention? - Currently under development by NICE, but only in patients with hypertension SIPS study: 3 cluster randomised controlled trials of brief interventions in primary care, emergency departments and probation services. Brief lifestyle counselling tool, patient information leaflet, Brief advice tool. Follow-up at 6 months and 12 months (AUDIT questionnaire)

SIPS study in Primary Care

Screening and treating the migrant population EACH - Ethnic Alcohol Counselling Hounslow Eastern Europe Advice Centre AA meetings for Polishspeaking attendees Tailored patient information leaflets?

Marian Bogusz, Stop Drinking! Come With Us and Build a Better Tomorrow, 1952. Jacek Cwikla, Untitled, 1984. American Journal of Public Health November 2010, Vol 100, No. 11

Hepatitis B Alazawi W et al. Br J Gen Pract 2014;64:e694-e702

Primary Care Management of Viral Hepatitis B Guidance This guidance has been been developed in collaboration with local specialists in Camden and Islington This is to assist GPs in decision making and is not intended to replace clinical judgment Newly Diagnosed Hepatitis BsAg positive patient Offer testing and immunization of the household Offer lifestyle advice regarding alcohol, obesity and hepatitis B Test for Hepatitis A and offer vaccination if not immune Consider Urgent referral if US demonstrates HCC ALT> 300 Evidence of decompensated liver disease i.e. ascites/ encephalopathy, jaundice Perform following tests in primary care: FBC, INR LFT (inc AST and ALT) & AFP HBeAg, HBeAb, HBV DNA viral load Hepatitis C, Hepatitis D HIV (offer) Ultrasound Liver scan Refer to secondary care Document co-morbidities. Special attention to psychiatric, cardiovascular and immune Attach all blood and US scan results See next page for guidance regarding secondary care pathway

Hepatitis B ~350 million worldwide >8% 2-8% <2% Adapted from Centre for Disease Control, USA

Hepatitis B in Migrants Late presentation (HCC, decompensated cirrhosis) Ethnicity confers additional HCC risk. 6 monthly AFP and USS: - Cirrhosis - Asian men >40 - Asian women >50 - African > 20 Do our responsibilities for contact tracing end at the border?

Hepatitis C Alazawi W et al. Br J Gen Pract 2014;64:e694-e702

Hepatitis C ~150 million worldwide >10% 2.5-10% 1-2.5% <1% Adapted from Centre for Disease Control, USA

Primary Care Management of Viral Hepatitis C Guidance This guidance has been been developed in collaboration with local specialists in Camden and Islington This is to assist GP s in decision making and is not intended to replace clinical judgment Newly Diagnosed Hepatitis C antibody patient HCV antibody positive patient discharged post treatment (RNA negative) Offer hepatitis A testing and vaccination Offer lifestyle advice regarding alcohol, obesity and hepatitis C Perform following tests in primary care including: FBC, INR AFP, LFT s (inc AST and ALT), TFT s HCV RNA viral load, HCV Genotype HIV (offer), HAV, HBV, HDV Ultrasound Liver scan Annual Review for Chronic Liver Disease FBC, LFT s, AFP Abnormal Tests If rising LFT s, follow abnormal LFT pathway and ensure relevant blood tests done (do not need repeat genotype) Refer to secondary care Document co-morbidities. Special attention to psychiatric, cardiovascular and immune Attach all results See next page for guidance regarding secondary care pathway Consider Urgent referral if US demonstrates HCC ALT> 300 Evidence of decompensated liver disease i.e. ascites/ encephalopathy, jaundice

Hepatitis C in Migrants Under-diagnosis Not being tested at the point of care Under-treatment Poor response to treatment Unequal access to care, lack of awareness of new treatments, Poor information management by Secondary care. Genotype 3 now the most difficult to treat, especially when cirrhotic

Summary The study of migrant populations is inherently reductionist and often conflates ethnicity, genetics, country of origin and even religion. An awareness of prevalence in country of origin is useful for targeted screening, particularly for viral hepatitis, but this must encompass patients with normal LFTs Certain migrant populations are at greater risk of NASH and a lack of response to lifestyle interventions does not necessarily indicate non-compliance. Studies of drinking patterns in migrant populations are of questionable utility, but interventions for ALD may be more effective if tailored to the target population There is an urgent issue with unequal access to diagnosis and treatment of HCV